Table 2.

ARs antagonists generally stabilize GABAA receptors microtransplanted to oocytes from dysplastic neocortices

Drug treatment (dose)Tested oocytes (frogs) [patients]IGABA, %, before treatment (n)IGABA, %, after treatmentP
PFCD
    ANR82 (100 nM) [A2A antagonist]41 (6) [6–9]62.1 ± 4.8 (6)47.5 ± 2.4<0.01
45.8 ± 2.1 (27)60.9 ± 1.5<0.001
    ANR94 (100 nM) [A2A antagonist]20 (4) [6 and 7]46.5 ± 2.0 (10)55.5 ± 2.4<0.001
    ANR152 (100 nM) [A2A & A1 antagonist]12 (2) [6]51.7 ± 2.8 (8)69.0 ± 2.4<0.001
    ANR235 (100 nM) [A3 antagonist]24 (4) [6–8]48.5 ± 3.3 (24)*50.7 ± 2.9*>0.5
AFCD
    ANR82 (100 nM) [A2A antagonist]22 (3) [10 and 11]75 (1)66.7-
51.6 ± 1.9 (18)69.4 ± 1.7<0.001
    ANR94 (100 nM) [A2A antagonist]23 (4) [10–12]56.2 ± 2.2 (13)72.6 ± 2.8<0.001
    ANR152 (100 nM) [A1 and A2A antagonist]12 (2) [10 and 12]51.7 ± 2.0 (9)64.5 ± 2.7<0.001
    ANR152 (10 nM) [A2A antagonist]11 (2) [12]59.7 ± 2.3 (9)67.2 ± 2.0<0.001
    Mix DPCPX (30 nM) [A1 antagonist]10 (2) [10]54.3 ± 4 (7)68.5 ± 4<0.001
    ANR152 (10 nM) [A2A antagonist]61.2 + 4 (3)58.8 ± 4*>0.5
    DPCPX (30 nM) [A1 antagonist]3 (1) [10]57.1 ± 1.3 (3)57.2 ± 0.7>.5
    ANR235 (100 nM) [A3 antagonist]8 (2) [10 and 11]42.6 ± 5.7 (8)*34.6 ± 3.5*>.5
  • n, number of oocytes responsive to AR antagonists. Set of cells in which rundown increases and n are in bold. IGABA (%) values represent the sixth IGABA amplitude normalized to the first of the rundown protocol.

  • *, Not significantly different.